Modamoda "MFDS misleads the public with absurd claims"... Sharp counterattack

Products of Modamoda.

[Asia Economy Reporter Moon Hyewon] Modamoda recently strongly criticized the Ministry of Food and Drug Safety (MFDS) regarding the renewed controversy over the ingredient 1,2,4-Trihydroxybenzene (hereinafter THB).

On the 27th, Modamoda stated in a press release, “The MFDS is making sophistical claims that mislead the public.”

The controversy began when Modamoda was selected as the number one in the hair category at the ‘Cosmoprof Las Vegas’ awards held recently in the United States, and the MFDS rebutted by saying, “It has never undergone a safety evaluation by the U.S. FDA,” and released a statement claiming, “Modamoda falsely advertised that its products were recognized for safety in the U.S.”

According to the MFDS press release dated the 25th, “(The U.S. Cosmoprof award criteria are) innovation, marketability, marketing impact, brand building, promotion and relationship-building capabilities, and proposals,” and “there is no award criterion that recognizes safety.”

However, Modamoda’s side stated that, contrary to the MFDS’s position, they have never claimed to have received a safety evaluation from the U.S. FDA. Modamoda said, “We said we were recognized for safety at Cosmoprof, but (the MFDS) distributed a press release that strongly caused misunderstandings as if Modamoda claimed to have proven safety with the U.S. FDA, which turned out not to be true,” and “on top of that, they even stated that they handed over Modamoda’s safety data to the U.S. FDA,” strongly criticizing the MFDS.

They added, “While not raising any issues with over 1,000 products from large corporations containing genotoxic substances distributed domestically, why is the MFDS showering Modamoda’s THB ingredient with political scrutiny rather than scientific verification? This cannot escape being called a typical double standard,” and “The government agency, which should support the global expansion of domestic companies, is actively raising issues with the U.S. FDA and trying to block overseas exports. The Yoon Seok-yeol administration must recognize the seriousness of the MFDS’s retaliatory administration and prepare countermeasures,” they raised their voice.

This content was produced with the assistance of AI translation services.